表紙
市場調查報告書

精準免疫治療技術創新改變人類健康(Health & Wellness)

Precision Immunotherapy Innovations Transforming Human Health and Wellness

出版商 Frost & Sullivan 商品編碼 913134
出版日期 內容資訊 英文 63 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
精準免疫治療技術創新改變人類健康(Health & Wellness) Precision Immunotherapy Innovations Transforming Human Health and Wellness
出版日期: 2019年09月20日內容資訊: 英文 63 Pages
簡介

許多企業正在開發針對癌症及自體免疫疾病的免疫療法。包含癌症治療的細胞治療、幹細胞應用、單株抗體、多株抗體、雙特異性抗體等。透過結合這些療法開發獨特的治療方法。

本報告研究精準免疫治療技術創新,彙整技術概要、癌症和自體免疫疾病的細胞治療、單株抗體、新型免疫療法概要、成長機會等情報。

第1章 摘要整理

第2章 技術概要

  • 免疫療法概要

第3章 癌症和自體免疫疾病的細胞治療

  • 癌症細胞治療的進步
  • 開發中的細胞療法
  • 基於幹細胞的細胞免疫療法
  • 抗B細胞成熟抗原CAR-T-細胞治療
  • 既有細胞療法
  • 紅血球治療
  • 定點照護的非病毒細胞治療平台、其他

第4章 癌症和自體免疫疾病的單株抗體

  • 抗體和蛋白質治療藥物的開發
  • 免疫療法的抗體
  • 抗體庫技術平台
  • 雙特異性、抗體細胞激素平台
  • 改善後天免疫反應的抗體、其他

第5章 新型免疫療法平台

  • 新技術可望改變癌症治療方法
  • 開發中的新癌症治療方法
  • 基於RNA的免疫療法、其他

第6章 新抗原、小分子、併用

  • 新抗原、小分子、併用的進步
  • 平台免疫療法產業
  • 透過AI的新抗原平台、其他

第7章 成長機會和活躍企業

  • 細胞治療
  • 抗體
  • 新興和併用方法

第8章 主要產業影響者

目錄
Product Code: D8D2

A Review of Advances in Cell Therapies, Antibodies, Fusion Proteins, and Other Innovative Approaches for Cancer Treatment

There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases. Current study describes some of the recent advances in immunotherapy, mostly cancer. These include refined cell therapies, stem cell applications in cancer treatment, monoclonal, polyclonal and bispecific antibodies. Some of exciting technologies like trispecific and multispecific fusion proteins and antibody derivatives are also covered. Combination of various immunotherpy approaches with / without modification and some of the unique approaches like photoimmunotherapy, RNA therapy, synthetic oncolytic viruses and latest artificial intelligence based platforms to develop neoantigens, peptide vaccines are discussed.

Table of Contents

1.0 Executive Summary

  • 1.1 Research Background: Innovating to Address Immunotherapies
  • 1.2 Research Scope: Emerging Immunotherapies
  • 1.3 Analysis Framework: Frost & Sullivan Core Value
  • 1.4 Research Methodology: Five Steps Toward Success
  • 1.5 Key Findings of Global Immunotherapies

2. Technology Snapshot

  • 2.1 Snapshot of Immunotherapies

3.0 Cell Therapies for Cancer and Autoimmune Diseases

  • 3.1 Advances in Cell Therapy for Cancer
  • 3.2 Cell Therapies in Development
  • 3.2 Cell Therapies in Development (continued)
  • 3.3 Stem Cell-based Cellular Immunotherapy
  • 3.4 Anti-B cell Maturation Antigen CAR-T-cell Therapy and Beyond
  • 3.5 Off-the-shelf Cell Therapies for Cancer and Autoimmune Diseases
  • 3.6 Red Cell Therapy for Cancer, Autoimmune, and Rare Diseases
  • 3.7 Nonviral Cell Therapy Platform for Point of Care Applications
  • 3.8 Controlled Cell Therapy Technology Platforms
  • 3.9 Nonviral Vector Platform for T-cell Therapy
  • 3.10 Living Immunotherapies for Cancer Treatment
  • 3.11 Mobilizing Cytotoxic Cellular Response to Attack Antibody-labelled Cancer Cells
  • 3.12 NK Activating Receptors and Peptide-based Cell Therapy Platforms

4.0 Monoclonal Antibodies (mAbs) for Cancer and Autoimmune Diseases

  • 4.1 Developments in Antibodies and Protein Therapeutics
  • 4.2 Antibodies for Immunotherapy
  • 4.3 Antibody Library Technology Platforms
  • 4.4 Bispecific and Antibody-cytokine Platforms
  • 4.5 Antibodies Improving Innate and Adaptive Immune Response
  • 4.6 Transgenic Mouse Producing Human Antibodies
  • 4.7 Antibody Producing Strong "Eat Me" Signals on Cancer Cells
  • 4.8 Improved Platforms for Bispecific and Trispecific Molecules
  • 4.9 Multispecific Antibodies with Specific Properties

5.0 Novel Immunotherapy Platforms

  • 5.1 Novel Technologies Poised to Change Cancer Therapeutics
  • 5.2 Novel Cancer Therapies in Development Immunotherapy Industry: Monoclonal Antibodies, Global, 2019
  • 5.3 Cancer Killing Through Illumination of Infrared Dye
  • 5.4 Nonnatural Virus Having Cancer Killing Activity
  • 5.5 Targeting Immune Check Points and Gangliosides
  • 5.6 RNA-based Immunotherapy for Cancer and Infectious Diseases
  • 5.7 Antibody Conjugation and DNA Vaccine Platform
  • 5.8 Dual-sided Fc Fusion Protein Platform

6.0 Neoantigens, Small Molecules, and Combinations

  • 6.1 Advances in Neoantigens, Small Molecules, and Combinations
  • 6.2 Neoantigens, Small Molecules, and Combination PlatformsImmunotherapy industry: Neoantigens, small molecules, and combinations, Global, 2019
  • 6.3 AI-powered Neoantigen Platform Trained on Patient's Data
  • 6.4 Neoantigen Platforms for Personalized Vaccines and Cell Therapy
  • 6.5 Small Molecule Therapeutics Coupled with Antibodies
  • 6.6 Cancer Immunotherapy and Immunosuppression
  • 6.7 B Cell Vaccine, Polyclonal Antibodies, and Oncolytic Virus
  • 6.8 Multiple Immunotherapy Under One Roof

7.0 Growth Opportunities and Companies to Action

  • 7.1 Growth Opportunity 1: Cell Therapy
  • 7.2 Growth Opportunity 2: Antibodies
  • 7.3 Growth Opportunity 3: Novel and Combination Approaches

8.0 Key Industry Influencers

  • 8.1 Industry Interactions
  • 8.1 Industry Interactions (continued)
  • Legal Disclaimer
Back to Top